Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial

This publication has 29 references indexed in Scilit:

• Analysis of survival adjusted for quality of life using the Q-TWiST function: Interface in R
  Computer Methods and Programs in Biomedicine, 2016
• Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the United Kingdom and the Netherlands
  International Journal of Colorectal Disease, 2014
• Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial
  Breast Cancer Research and Treatment, 2014
• Health-related quality of life in ovarian cancer patients and its impact on clinical management
  Expert Review of Pharmacoeconomics & Outcomes Research, 2011
• Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
  Quality of Life Research, 2011
• Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
  Health and Quality of Life Outcomes, 2007
• Evaluating Health-Related Quality of Life in Cancer Clinical Trials: The National Cancer Institute of Canada Clinical Trials Group Experience
  Value in Health, 2007
• Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study
  BMC Cancer, 2006
• Psychological well being and quality of life in ovarian cancer survivors
  Cancer, 2003
• Reliability and Validity of the Functional Assessment of Cancer Therapy–Ovarian
  Journal of Clinical Oncology, 2001